Compare GRC & ATAI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | GRC | ATAI |
|---|---|---|
| Founded | 1933 | 2018 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Fluid Controls | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.9B | 1.6B |
| IPO Year | 1994 | 2025 |
| Metric | GRC | ATAI |
|---|---|---|
| Price | $74.89 | $4.54 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 8 |
| Target Price | N/A | ★ $15.88 |
| AVG Volume (30 Days) | 86.5K | ★ 4.1M |
| Earning Date | 04-23-2026 | 05-11-2026 |
| Dividend Yield | ★ 1.04% | N/A |
| EPS Growth | ★ 32.03 | N/A |
| EPS | ★ 0.68 | N/A |
| Revenue | ★ $682,389,000.00 | $4,089,000.00 |
| Revenue This Year | $6.62 | N/A |
| Revenue Next Year | $4.66 | N/A |
| P/E Ratio | $110.06 | ★ N/A |
| Revenue Growth | 3.44 | ★ 1227.60 |
| 52 Week Low | $34.96 | $2.00 |
| 52 Week High | $79.54 | $6.73 |
| Indicator | GRC | ATAI |
|---|---|---|
| Relative Strength Index (RSI) | 55.18 | 61.78 |
| Support Level | $43.10 | $3.46 |
| Resistance Level | $79.02 | $4.68 |
| Average True Range (ATR) | 2.25 | 0.22 |
| MACD | -0.28 | 0.03 |
| Stochastic Oscillator | 62.97 | 93.94 |
Gorman-Rupp Co designs, manufactures, and globally sells pumps & pump systems for use in water, wastewater, construction, dewatering, industrial, petroleum, original equipment, agriculture, fire protection, heating, ventilating & air conditioning, military, and other liquid-handling applications. It operates in one business segment, the manufacture & sale of pumps and pump systems, and generates revenue from the same. Geographically, it generates the majority of its revenue from the United States.
AtaiBeckley Inc is a clinical-stage biopharmaceutical company on a mission to transform patient outcomes by developing effective, rapid-acting, and convenient mental health treatments. AtaiBeckley's pipeline of novel therapies includes BPL-003 (mebufotenin benzoate nasal spray) for treatment-resistant depression (TRD), VLS-01 (DMT buccal film) for TRD, and EMP-01 ((R)-MDMA HCI) for social anxiety disorder, which are in Phase 2 clinical development.